How is GHRP-2 / GHRP-6 administered?
This describes how GHRP-2 / GHRP-6 is typically administered in clinical and research references, not a self-administration guide. The usual route is Subcutaneous, on a 1-3x daily schedule, generally over 8-12 weeks on, 4 weeks off. Specific dosing is individual and beyond general information, and human evidence for GHRP-2 / GHRP-6 is limited.
Administration at a glance (reference data)
- Route: Subcutaneous
- Schedule: 1-3x daily
- Cycle length: 8-12 weeks on, 4 weeks off
- Half-life: ~15-30 minutes
References
- Effects of GH-releasing peptide-2 (GHRP-2) on body composition — Bowers CY et al., JCEM, 2004
- Estradiol regulates GH-releasing peptide's interactions with GH-releasing hormone and somatostatin in postmenopausal women — Norman C et al., European Journal of Endocrinology, 2014
- Growth hormone-independent cardiotropic activities of growth hormone-releasing peptides in normal subjects, in patients with growth hormone deficiency, and in patients with idiopathic or ischemic dilated cardiomyopathy — Broglio F et al., Endocrine, 2001
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on GHRP-2 / GHRP-6
Last updated 2026-06-15.